A US appeals court has ruled that Actavis’s attempt to force Alzheimer’s patients to switch from one medication to another before generic companies entered the market was anti-competitive.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Second Circuit, Namenda, product hopping, Actavis, Eric Schneiderman, patent